HOLX vs. TMO: Which Diagnostic Giant Is the Stronger Buy Today?
Diagnostic leaders Hologic and Thermo Fisher post raised outlooks, acquisitions and strong product momentum.
Zacks·5d ago
More News
Hologic's Strong International Traction to Continue Despite Headwinds
HOLX's global push shows strength, with surgical growth and rising diagnostics use offsetting near-term challenges.
Zacks·9d ago
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
Zacks·11d ago
Beat the Market the Zacks Way: CommScope, Micron, Oracle in Focus
Zacks' strategies continue to outpace the market in 2025, with standout gains from CommScope, Micron, Oracle, and others across multiple model portfolios.
Zacks·12d ago
Hologic's Panther Fusion Signals More Molecular Diagnostics Upside
HOLX's Panther Fusion expands its diagnostics menu, fueling assay growth and unlocking more upside in molecular testing.
Zacks·23d ago
Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·24d ago
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.
Zacks·25d ago
Hologic (HOLX) Down 0.3% Since Last Earnings Report: Can It Rebound?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·29d ago
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio?
TMO's growth, driven by new partnerships and strong end markets, faces challenges from macro pressures and fierce competition.